HOME >> MEDICINE >> TECHNOLOGY |
SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process.
Studies accepted for presentation include
*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of exogenous prostaglandin comparing the efficacy and safety of the misoprostol vaginal insert (MVI) 200 mcg to the dinoprostone vaginal insert for reducing time to vaginal delivery in pregnant women at term.
For further information, contact:
Leila Boukassi
MSL New York
leila.boukassi@mslgroup.com; 646.500.7735
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.
SOURCE Ferring Pharmaceuticals Copyright©2012 PR Newswire. All rights reserved |